Posts tagged ‘ESMO Conference 2011’
Alpharadin may change standard of care for prostate cancer patients with bone mets
September 29th, 2011
Daedalus
We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city.
Sally Church (@MaverickNY) live tweeted several sessions from the meeting and was name the “Top Twitter Influencer” for the #EMCC2011 hashtag. You can catch up with the tweets fron ECCO ESMO ESTRO 2011 on Pharma Strategy Blog.
Source: Fox epractice
Pieter Droppert (@3NT) has written several posts on biotech strategy blog about the exciting data for radium-223 (Alpharadin) in advanced prostate cancer that was presented in Stockholm.
He also produced a video of the media briefing by Dr Chris Parker from the Royal Marsden Hospital where the ALSYMPCA phase 3 trial results were reviewed. It is well worth watching!
Please contact us if you would like to learn more about the fast moving Prostate Cancer market and how pharma marketing strategy may be impacted by the new products in development such as radium-223 (Alpharadin), that is on fast track for FDA approval in 2012.
It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride.
The phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) in Stockholm this past weekend.
Pieter Droppert has two posts on Biotech Strategy Blog from the Congress about the potentially “practice changing” Alpharadin prostate cancer data:
- Alpharadin will be a new treatment option for Prostate Cancer
- Alpharadin Prostate Cancer data will be “practice changing”
He also took the opportunity to interview Dr Chris Parker, Consultant Clinical Oncologist at The Royal Marsden Hospital, who presented the ALSYMPCA phase 3 trial results, and a video blog post will follow.
Live conference twitter board at #EMCC2011
Sally Church on Pharma Strategy Blog aggregated all the tweets from the 2011 ESMO ECCO congress in Stockholm. With only a few people tweeting, the twitter stream doesn’t report all the news, but does give a flavor of an excellent cancer meeting with a good balance of science and clinical data.
It’s an exciting time for prostate cancer patients and physicians with multiple new treatment options on the horizon. However, the fast moving and dynamic prostate cancer market is likely to present Pharma/Biotech marketing strategy professionals with opportunities and challenges. Alpharadin is on the fast track to FDA approval in 2012.
The 2011 Stockholm Multidisciplinary Cancer Congress (more commonly known as ECCO 2011 or ESMO 2011) is underway in Stockholm, Sweden.
Pieter Droppert (@3NT) will be writing on Biotech Strategy Blog from the meeting and in particular the new data on prostate cancer that will be presented, in particular the phase 3 Alpharadin ALSYMPCA trial data that is a late breaking abstract.
Sally Church (@MaverickNY) will be covering several sessions live on Twitter. On Pharma Strategy Blog, Sally is aggregating the live tweets from the meeting (#EMCC2011). If you are unable to be in Stockholm for the meeting this weekend, you can follow the action remotely. As Sally would say, “check it out.”
Icarus Consultants’ social media and oncology expert, Sally Church, is also into business productivity.
At the many cancer conferences she attends each year such as ASCO, ASH, AACR and the forthcoming ESMO/ECCO/ESTRO meeting in Stockholm, an iPad is now Sally’s preferred choice of device to travel with.
How does Sally use an iPad to cover these medical conferences?
In an informative post on Pharma Strategy Blog, Sally outlines the apps that she uses and how they improve her productivity! Anyone who has seen Sally at a conference knows she covers a lot of ground – quite literally in the case of the miles that one walks at ASCO!
What is Sally’s favorite app?
Try the Howard Hughes Medical Institute (HHMI) quarterly bulletin, that according to Sally is “a truly beautiful combination of art and science that is a pleasure to read.”
You can read more on Pharma Strategy Blog on how to use an iPad for improved productivity in science, medicine and the pharma industry.
I’ll be asking for one for Xmas this year too!
Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending.
Photo: Max Anderson
We will be at ECCO 16 – ESMO 36 in Stockholm from September 23 – 27, 2011.
The jointly organized multidisciplinary cancer congress of the European CanCer Organisation (ECCO ) and European Society for Medical Oncology (ESMO) covers a wide range of topics from basic and translational science to surgery, radiotherapy, medical oncology, advocacy and care.
You can access the preliminary programme for the meeting here.
Given the early cut-off date for submission of abstracts for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, we expect the ECCO/ESMO Stockholm meeting will publish interesting data on a number of new products in development.
In anticipation of the meeting, Sally Church will be analyzing the abstracts (once they are available) for what’s hot and you can expect a pre-meeting video blog post. If you missed Sally’s ASCO preview video, it is well worth watching.
Hope to see you in Stockholm.
Photo: Stan Shebs
